Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Tap

Showing results (201-210 of 235) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgeryEvan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2019
Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical OncologySumanta K Pal, Michael J Miller, Neeraj Agarwal, et al.
NPJ Precision Oncology|May 5, 2026
An international framework for clinical translation of molecular classifiers in osteosarcomaAmanda E Marinoff, Michaela Nathrath, David S Shulman, et al.
The New England Journal of Medicine|December 22, 2018
Sorafenib for Advanced and Refractory Desmoid TumorsMrinal M Gounder, Michelle R Mahoney, Brian A Van Tine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal TumorPing Chi, Li-Xuan Qin, Bastien Nguyen, et al.
Lancet (London, England)|June 6, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialHans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, et al.
JAMA Oncology|July 8, 2021
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical TrialAndrew J Wagner, Paul L Severson, Anthony F Shields, et al.
Nature Cancer|March 1, 2024
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapyAjay Subramanian, Neda Nemat-Gorgani, Timothy J Ellis-Caleo, et al.
Pageof 24

Showing results (201-210 of 235) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgeryEvan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2019
Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical OncologySumanta K Pal, Michael J Miller, Neeraj Agarwal, et al.
NPJ Precision Oncology|May 5, 2026
An international framework for clinical translation of molecular classifiers in osteosarcomaAmanda E Marinoff, Michaela Nathrath, David S Shulman, et al.
The New England Journal of Medicine|December 22, 2018
Sorafenib for Advanced and Refractory Desmoid TumorsMrinal M Gounder, Michelle R Mahoney, Brian A Van Tine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal TumorPing Chi, Li-Xuan Qin, Bastien Nguyen, et al.
Lancet (London, England)|June 6, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialHans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, et al.
JAMA Oncology|July 8, 2021
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical TrialAndrew J Wagner, Paul L Severson, Anthony F Shields, et al.
Nature Cancer|March 1, 2024
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapyAjay Subramanian, Neda Nemat-Gorgani, Timothy J Ellis-Caleo, et al.
Pageof 24